title: Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.
abstract: 33 patients with locally advanced non-small cell lung cancer entered a study of neoadjuvant chemotherapy to evaluate the response rate with ifosfamide/cisplatin/etoposide and the complete resection rate and safety of surgery following chemotherapy. Chemotherapy with cisplatin 25 mg/m2, ifosfamide 1.5 g/m2, and etoposide 100 mg/m2 was given on days 1-4 of a 21 day cycle and repeated for three cycles. For responders, surgery was done 15-20 days after haematological recovery. Chemotherapy induced 5 complete responses (15%) and 18 partial responses (55%). 77% of the 33 patients had grade 3-4 neutropenia and 60% grade 3-4 thrombocytopenia. 1 patient died with a central nervous system haemorrhage. Thoracotomy was done in 21 patients but resection was only possible in 20 (61%). A complete resection was achieved in 18 patients (55%). Histology was negative for the 5 complete responses. Surgery induced no morbidity. A high response rate may be obtained with ifosfamide, cisplatin and etoposide neoadjuvant chemotherapy allowing a high complete resection rate.
authors.affiliation: Hôpital l'Aiguelongue, Montpellier, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Pujol
authors.forename: J F
authors.initials: JF
authors.lastname: Rossi
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: J P
authors.initials: JP
authors.lastname: Daurès
authors.forename: P
authors.initials: P
authors.lastname: Rouanet
authors.forename: J Y
authors.initials: JY
authors.lastname: Douillard
authors.forename: J B
authors.initials: JB
authors.lastname: Dubois
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: H
authors.initials: H
authors.lastname: Mary
authors.forename: P
authors.initials: P
authors.lastname: Godard
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced; D010865:Pilot Projects; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide